Monthly news from Pharmaprojects
 October 2006
Pharmaprojects reports in its October 2006 update 186 new chemical entities, formulations, biologicals and gene therapies which have been identified for the first time, under development by 111 companies.
It also reports 26 new licensing opportunities, of which 22 are available worldwide. Five products have been launched for the
first time and six have received their first approval, including Xechem’s Nicosan
(niprisan), which is approved in Nigeria for the treatment of sickle cell anaemia;
and Epeius Biotechnologies’ Rexin-G, a gene therapy for solid tumours which is
registered in the Philippines. First registration applications have been filed
for three products, while 56 projects have moved into a more advanced stage of
clinical development. Full details can be found in the October update to Pharmaprojects in print, the Pharmaprojects CD-ROM, the Pharmaprojects online files and Pharmaprojects on the Web (now updated weekly).
Among this month’s highlights are 36 new companies, including Austrian firm Eucodis,
which is developing biopharmaceuticals and antibodies via in vivo recombination
somatic hypermutation; and Italian firm Bio3 Research, which is focusing on HMGB1-related
cardiovascular disorders and the use of HMGB1 in connective tissue regeneration.
Among companies at which new drug development targets have been identified are
Astellas, which is investigating inhibitors of calcium channel voltage-dependent
α1F subunit for the treatment of atrial fibrillation and stable angina; and NephroGenex,
which is developing inhibitors of Goodpasture antigen binding protein for the
therapy of glomerulosclerosis. The focus of this month’s report in our Update
Analysis is the recent International AIDS Conference. Other significant events
this month include new drugs reported at the fall American Chemical Society meeting,
the EU approval of deferasirox, and a deal between Ligand and Eisai to commercialize a
number of Ligand products.
For more information, contact
Ian Lloyd, Managing Editor
Telephone: +44 (0)20 7017 6886
Facsimile: +44 (0)20 7017 6898
Top
|
.gif)
